Investor Relations

Corporate Profile

Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological disorders who have unmet medical needs. Established by founder Paragon Biosciences LLC, our mission is to positively impact the lives of those living with rare diseases who are so often underserved.
 

In August of 2019, Harmony Biosciences received FDA approval for its first commercial product, WAKIX® (pitolisant) tablets. Harmony is currently evaluating pitolisant for broader applications in neurological disorders that may be mediated by the H3 receptor. See product pipeline for further details.

Minimum 15 minutes delayed. Source:

News Releases

Oct 30, 2024

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

PLYMOUTH MEETING, Pa. , Oct. 30, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public offering of an aggregate of 8,000,000 shares of the Company's common stock, par value $0.00001 per
Oct 29, 2024

Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders

PLYMOUTH MEETING, Pa. , Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to 8,000,000 shares of the Company's common stock, par value $0.00001 per share ("Common Stock"), by
Oct 29, 2024

HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS

WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension

Oct 16, 2024

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024

PLYMOUTH MEETING, Pa. , Oct. 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October 29, 2024 , before the open of the U.S. financial markets.
Oct 15, 2024

HARMONY BIOSCIENCES ANNOUNCES ITS NEWEST PROGRESS AT THE HEART AND PATIENTS AT THE HEART AWARDEES

Harmony Biosciences has announced the newest recipients of its Progress at the Heart and Patients at the Heart Awards programs, which provide funding support for community and nonprofit organizations working to develop innovative, patient-centric initiatives that help drive meaningful change for

Oct 01, 2024

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY

BP1.15205 Data Indicates Potential Best-In-Class Orexin-2 Agonist Based on Highest Potency New Data Shows Clinically Meaningful Sustained Efficacy of Pitolisant in Patients with Idiopathic Hypersomnia in Long-Term Extension Study; On Track to Submit sNDA in Q4 2024 Preliminary Data Establish
View All

Events

View All

Contact Information